semaglutide bimagrumab plus alone or in combination for the treatment of obesity: a randomized phase 2 trial Weight Loss That Preserves Muscle:

Despite how these products are promoted, presented and packaged, consumers have no way of knowing whether they are authorised medicines or if they have been subjected to any safety or quality assessments

Based on SURMOUNT-5 data, average monthly weight loss at therapeutic doses is approximately 1.5 to 2.5% of starting body weight

Some people get sulfur burps, and others dont

Patients should discuss with their provider whether a compounded formulation might support more personalized treatment outcomes

Evidence boundary No human clinical trial has tested cagrilintide + tirzepatide together

Combined approach: Many clinics now offer Lipo-C alongside GLP-1 medications, using lower GLP-1 doses while maintaining robust fat loss through complementary mechanisms